Released Mar 5, 2026, after the close
10-K filed Mar 5, 2026, 64 days after period end · 0001104659-26-024153
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$6.72M$6.72M derived+66.8% vs Q4 2024+32.8% vs Q3 2025
Net Income-$8.17M-$8.17M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$3,991,000+34.7%
Operating Incomederived-$7,369,000N/M
Operating Cash Flowderived-$6,566,000N/M
Margins · derived
Gross margin59.4%−14.2 pt vs Q4 2024
Operating margin-109.7%+97.6 pt vs Q4 2024
Net margin-121.7%+1.2 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures |
|---|---|---|
| Revenue | $6.72M | $4.03M |
| Net Income | -$8.17M | -$4.95M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR